Young Shin Cho

TL;DR: By interrogating data from a large-scale short hairpin RNA–mediated screen across 390 cancer cell line models, it is found that the viability of MTAP-deficient cancer cells is impaired by depletion of the protein arginine methyltransferase PRMT5.

TL;DR: Optimization efforts are reported on toward the identification of clinical candidate IDH305, a potent and selective mutant IDH1 inhibitor that has demonstrated brain exposure in rodents and has progressed into human clinical trials for the treatment of cancers with IDH 1 mutation.

TL;DR: Identification and structure-guided optimization of a series of 4-(pyrazol-4-yl)-pyrimidines as selective CDK4/6 inhibitors is reported herein.

TL;DR: In this article, the use of a compound of formual (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

TL;DR: In this article, a pyrrolopyrimidine compound of formula (I) was proposed for the treatment of CDK4/6 mediated diseases, such as cancer, including mantle cell lymphoma, liposarcoma, non small cell lung cancer, melanoma, squamous cell esophageal cancer and breast cancer.